2020
Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia
Gautam S, Cohen AJ, Stahl Y, Toro P, Young GM, Datta R, Yan X, Ristic NT, Bermejo SD, Sharma L, Restrepo M, Dela Cruz CS. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax 2020, 75: 974-981. PMID: 32826284, DOI: 10.1136/thoraxjnl-2020-214896.Peer-Reviewed Original ResearchConceptsPure viral infectionBacterial coinfectionViral infectionInfluenza infectionSevere respiratory viral infectionsAbility of procalcitoninRetrospective cohort studyViral respiratory infectionsRespiratory viral infectionsMarker of severityRespiratory viral illnessSevere viral infectionsSpecificity of procalcitoninCharacteristic curve analysisCellular modelHigher procalcitoninProcalcitonin expressionElevated procalcitoninCohort studyViral illnessRespiratory infectionsAntibiotic administrationBacterial pneumoniaSevere diseaseProcalcitoninReply to Suri et al.: COVID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity?
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang F, Xie L, Sharma L, Dela Cruz CS, Qin E. Reply to Suri et al.: COVID-19 Real-Time RT-PCR: Does Positivity on Follow-up RT-PCR Always Imply Infectivity? American Journal Of Respiratory And Critical Care Medicine 2020, 202: 148-148. PMID: 32401535, PMCID: PMC7328309, DOI: 10.1164/rccm.202004-1458le.Commentaries, Editorials and LettersPersistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, Li BY, Liu HX, Li BA, Qin CF, Peng XH, Wang FS, Xie LX, Chen Z, Dela Cruz CS, Sharma L, Qin EQ. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2585-2591.e1. PMID: 32574840, PMCID: PMC7305869, DOI: 10.1016/j.jaip.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBetacoronavirusC-Reactive ProteinChildChild, PreschoolComorbidityCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHumansInfantInflammationInflammation MediatorsInterleukin-6MaleMiddle AgedPandemicsPneumonia, ViralReal-Time Polymerase Chain ReactionRespiration, ArtificialSARS-CoV-2Severity of Illness IndexYoung AdultConceptsDisease severityViral clearanceViral persistenceDisease outcomeCOVID-19Viral presenceExtensive lung involvementC-reactive proteinEffective antiviral therapyCoronavirus disease 2019Severe disease outcomesHost antiviral mechanismsInfectious viral particlesImmunomodulatory therapyInflammatory markersLung involvementRespiratory supportClinical courseAntiviral therapyIL-6Viral reactivationClinical managementInflammatory responseChest imagingDisease 2019Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang FS, Xie L, Sharma L, Dela Cruz CS, Qin E. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. American Journal Of Respiratory And Critical Care Medicine 2020, 201: 1150-1152. PMID: 32200654, PMCID: PMC7193851, DOI: 10.1164/rccm.202003-0524le.Peer-Reviewed Original ResearchProfiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases 2020, 71: 778-785. PMID: 32198501, PMCID: PMC7184472, DOI: 10.1093/cid/ciaa310.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Humoral responseSymptom onsetIgM ELISAProbable casesEarly humoral responseHost humoral responseMajor healthcare threatCoronavirus disease 2019IgA antibody detectionCOVID-19Viral nucleic acidsQuantitative polymerase chain reactionNovel coronavirus diseaseFalse-negative resultsMedian durationAntibody testingIgG responsesIgM antibodiesInfected patientsPolymerase chain reactionPositive rateDisease 2019Healthcare threatSubclinical casesEpidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China
Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA 2020, 323: 1092-1093. PMID: 32031568, PMCID: PMC7042871, DOI: 10.1001/jama.2020.1623.Peer-Reviewed Original ResearchProtecting health-care workers from subclinical coronavirus infection
Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. The Lancet Respiratory Medicine 2020, 8: e13. PMID: 32061333, PMCID: PMC7128440, DOI: 10.1016/s2213-2600(20)30066-7.Commentaries, Editorials and Letters
2018
Impact of Cigarette Smoke Exposure on the Lung Fibroblastic Response after Influenza Pneumonia
Lee SW, Sharma L, Kang YA, Kim SH, Chandrasekharan S, Losier A, Brady V, Bermejo S, Andrews N, Yoon CM, Liu W, Lee JY, Kang MJ, Dela Cruz CS. Impact of Cigarette Smoke Exposure on the Lung Fibroblastic Response after Influenza Pneumonia. American Journal Of Respiratory Cell And Molecular Biology 2018, 59: 770-781. PMID: 30110182, PMCID: PMC6293077, DOI: 10.1165/rcmb.2018-0004oc.Peer-Reviewed Original ResearchConceptsCigarette smoke exposureLungs of miceInfluenza infectionInfluenza virusBAL fluidSmoke exposureGrowth factor-β1 levelsAir-exposed lungsInfluenza-infected miceSignificant lung injuryFibroblastic responseLung-derived fibroblastsProtein-positive cellsGrowth factor-β1Influenza pneumoniaDifferent time pointsLung injurySmoking groupSignificant morbidityCS exposureMurine modelFibrotic responseΒ1 levelsFactor-β1Weight recovery